Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure (RURAL-HF)
Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure - the RURAL-HF Trial
The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital.
The main questions it aims to answer are:
- Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months?
- Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months?
- Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care?
Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life.
Participants will:
- Use a scale, blood pressure cuff, and activity tracker at home for 3 months
- May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group
- Complete video or phone study visits when they join, at 3 months, and at 6 months
- Answer questions about their heart failure symptoms and quality of life at each visit
- Some participants may also be asked to take part in an interview about their experience.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Background and Rationale:
Rural communities experience persistent and widening disparities in cardiovascular outcomes, driven by adverse social determinants of health, limited access to specialty care, and structural barriers to timely treatment. Heart failure (HF) exemplifies these inequities, with rural patients experiencing higher mortality and poorer access to acute and longitudinal care despite a growing and aging HF population. Although guideline-directed medical therapy (GDMT) substantially improves outcomes in both heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), real-world uptake and dose optimization remain low, particularly in rural settings, largely due to limited access to cardiac care, fragmented follow-up, and implementation challenges rather than true contraindications.
Telemedicine and remote patient monitoring (RPM) offer a practical strategy to address these barriers by expanding access to specialty input, enabling close physiologic monitoring, and supporting safe titration of GDMT medications without the need for frequent in-person visits. While early studies suggest that telehealth-enabled GDMT optimization can improve therapy uptake and outcomes, these approaches have not been rigorously evaluated in rural populations. This study addresses a critical evidence gap by testing a telemedicine-enabled, remote monitoring-supported strategy tailored to rural healthcare delivery, with the goal of improving GDMT optimization and reducing rural-urban disparities in HF care.
Study Design:
RURAL-HF is a randomized, open-label, Type 1 hybrid effectiveness-implementation trial comparing RPM alone vs. RPM combined with NT-proBNP-guided, provider-to-provider GDMT up-titration in patients recently hospitalized for HF in rural communities. Both arms receive remote monitoring devices for the first 90 days, isolating the effect of the NT-proBNP-guided GDMT titration intervention itself. The simultaneous collection of GDMT prescription, clinical, and implementation outcomes will inform future use and scalability should the intervention prove effective.
Participants will be enrolled at discharge from the index HF hospitalization or within 2 weeks of discharge. Participants will be randomly assigned 1:1 using a computerized algorithm. Block randomization will be performed by trial site and stratified by HF subtype (HFrEF/HFmrEF vs HFpEF) using REDCap. All recruitment and informed consent procedures will be conducted virtually using secure, HIPAA-compliant telehealth platforms. Blinding is not feasible because up-titration recommendations must be provided on the basis of physiologic data from remote monitoring.
Remote Patient Monitoring (Both Arms):
All participants, regardless of study arm, receive a cellular-connected device kit at enrollment. The kit includes a cellular-connected weight scale, a cellular-connected blood pressure and heart rate monitor, and a wrist-based watch that measures physical activity (step count). Devices arrive pre-configured and connect automatically to existing 4G/5G cellular networks, with no setup or home internet access required. This cellular-based approach enhances generalizability to rural populations by leveraging existing cellular tower infrastructure rather than requiring home broadband.
Participants are prompted to submit weight, heart rate, and blood pressure twice weekly for the first 6 weeks, decreasing to once weekly if no alert occurs, and returning to twice weekly if a new alert occurs. Remote monitoring alerts are reviewed, actioned, and closed by the study team. Active remote monitoring occurs from enrollment through 90 days for both arms.
RPM + NT-proBNP + GDMT Up-titration Arm:
The study team will provide GDMT initiation and titration recommendations to the participant's outpatient care team (primary care provider or cardiologist) on the basis of review of remote monitoring data. Recommendations will be delivered through asynchronous communication via the electronic health record, and the study team will offer at least one synchronous consultation (video or telephone) during the initial 90-day titration period. During the first 90 days post-discharge, the study team will review biometric data at least weekly and provide specific, evidence-based recommendations at one-to-two-week intervals until optimal or maximally tolerated GDMT is achieved. Recommendations will include specific medication suggestions (drug, dose, titration schedule) and laboratory-based monitoring instructions.
The study will employ a structured protocol integrating NT-proBNP levels, potassium, eGFR, and physiological safety parameters to guide GDMT optimization. Laboratory monitoring, including NT-proBNP and basic metabolic panels, will occur at weeks 2 and 6 as part of routine clinical care. NT-proBNP levels that remain stable or decline compared with pre-discharge baseline indicate safe conditions for beta-blocker up-titration, while NT-proBNP increases of more than 10% above pre-discharge levels will suggest withholding beta-blocker up-titration and instead increasing diuretic therapy to address potential worsening congestion. The participant's outpatient care team will implement recommendations through clinical encounters conducted according to their standard practice patterns. This approach is informed by STRONG-HF, which was associated with significantly greater uptake of GDMT and reduced risk of HF hospitalization or death at 180 days.
RPM Alone Arm:
Participants in the RPM alone arm receive the same device kit and remote monitoring for 90 days but do not have NT-proBNP testing or study-team GDMT titration recommendations. Remote monitoring alerts for this arm will be sent to the provider without recommendations for GDMT up-titration. Providers will receive general education surrounding GDMT use for patients with HF, and GDMT management is otherwise delivered according to standard community practice patterns.
Follow-up:
There will be three virtual study visits during the 6-month study period: a screening and baseline visit at enrollment, a 3-month follow-up visit coinciding with the end of the active 90-day RPM/GDMT titration period, and an end-of-study visit at 6 months. Between 90 days and 6 months, participants in both study arms will receive standard care from their outpatient providers without active study team intervention.
Statistical Analysis:
The primary endpoint will be analyzed using a stratified (by HF subtype), hierarchical win ratio approach, in which every participant in the RPM + NT-proBNP + GDMT arm is compared with every participant in the RPM alone arm over a shared follow-up time. The primary endpoint components and their hierarchy were determined after a survey of patients with HF, who noted that preventing mortality was the most important treatment outcome, followed by improving quality of life and avoiding hospitalization. A total of 598 participants will provide 80% power to detect a weighted stratified win ratio of 1.34 using a one-sided stratified win ratio Z-test with a Type I error rate of 0.025. The intent-to-treat population will include all randomized participants, analyzed according to their assigned treatment group. Pre-specified subgroup analyses of the primary endpoint will be conducted by sex, type of HF (HFrEF/HFmrEF vs. HFpEF), and racial/ethnic group.
Implementation Evaluation:
Implementation will be evaluated using the RE-AIM framework (reach, effectiveness, adoption, implementation fidelity, and maintenance), guided by the Implementation Research Logic Model and the Consolidated Framework for Implementation Research. An explanatory sequential mixed-methods design will combine quantitative implementation metrics with semi-structured key informant interviews with patients and caregivers (n=36, equally across study arms) and providers (n=12). Interviews will be audio or video recorded, transcribed verbatim, de-identified, and analyzed using rapid thematic analysis in Dedoose.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Ambarish Pandey, MD
- Phone Number: 734-647-4440
- Email: pandeyam@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Principal Investigator:
- Ambarish Pandey, MD
-
Contact:
- Ambarish Pandey, MD
- Phone Number: 734-936-3500
- Email: pandeyam@med.umich.edu
-
-
Texas
-
Plano, Texas, United States, 75093
- Baylor Scott & White Cardiac Consultants - Plano
-
Contact:
- Neil Keshvani
- Phone Number: 469-800-4400
- Email: neil.keshvani@bswhealth.org
-
Principal Investigator:
- Neil Keshvani, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years old
- Hospitalization for heart failure (HF) with intravenous diuretic use, with randomization within 14 days of discharge
- Residing in a rural area (home address in a rural area as defined by the Federal Office of Rural Health Policy)
- Established outpatient care (cardiology or primary care physician) at the participating sites
- Eligible to receive at least 2 of 4 guideline-directed medical therapy (GDMT) classes for HF with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF; beta-blocker, ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), or at least 1 of 3 GDMT classes for HF with preserved ejection fraction (HFpEF; ACE inhibitor/ARB/ARNi, MRA, SGLT2 inhibitor), and not on target doses of these medication classes
- Able to communicate with the study team via telephone or videoconference for study-related assessments and follow-up
Exclusion Criteria:
- Stage D HF under consideration for or a recipient of advanced HF therapies, including left ventricular assist device (LVAD), heart transplant, or inotrope therapy
- Discharge disposition to a nursing home, inpatient rehabilitation facility, or long-term care facility
- Potassium > 5.5 mmol/L
- End-stage kidney disease or eGFR < 25 mL/min/1.73 m²
- Inability to provide informed consent
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Remote patient monitoring + NT-proBNP & provider-to-provider support
Participants receive a cellular-connected device kit (weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker) with remote monitoring for 90 days following enrollment. In addition, the study team recommends NT-proBNP and basic metabolic panel testing at weeks 2 and 6, which the participant's outpatient care team may obtain as part of routine clinical care. The study team reviews biometric and laboratory data at least weekly and delivers specific, evidence-based GDMT initiation and titration recommendations (drug, dose, titration schedule, and laboratory monitoring instructions) to the participant's outpatient care team through asynchronous electronic health record communication at one-to-two-week intervals throughout the 90-day titration period. At least one synchronous video or telephone consultation is offered, with additional consultations available at the provider's preference. The participant's outpatient care team implements all medication changes. |
The study team reviews remote monitoring data at least weekly, along with NT-proBNP and basic metabolic panel results from testing recommended at weeks 2 and 6 and obtained as part of routine clinical care. Recommendations for GDMT initiation and up-titration to optimal or maximally tolerated doses (drug, dose, titration schedule, and laboratory monitoring) are sent to the outpatient care team through the electronic health record every 1 to 2 weeks for 90 days, with at least one video or telephone consultation offered. A structured protocol integrating NT-proBNP, potassium, eGFR, blood pressure, and heart rate guides titration. Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days. |
|
Active Comparator: Remote patient monitoring (RPM) alone
Participants receive the same cellular-connected device kit with remote monitoring for 90 days following enrollment. The study team may send safety alerts from remote monitoring to the participant's outpatient provider, without recommendations for GDMT up-titration. No recommendations for NT-proBNP testing and GDMT titration recommendations will be sent out by the study team. GDMT management, outpatient follow-up, and laboratory monitoring are delivered according to standard community practice by the participant's primary care provider or cardiologist. |
Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hierarchical Composite of All-Cause Mortality, Heart Transplantation or Ventricular-Assist Device, Heart Failure Hospitalizations, and Improvement in Kansas City Cardiomyopathy Questionnaire Score
Time Frame: Baseline to 180 days
|
The primary endpoint is a hierarchical composite of all-cause mortality, heart transplantation or ventricular-assist device, HF hospitalization (yes/no), total number of HF hospitalizations, or a >5-point improvement in the Kansas City Cardiomyopathy Questionnaire (KCCQ). The endpoint will be assessed at 6 months using a stratified, hierarchical win ratio approach. |
Baseline to 180 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of participants achieving optimal or maximally tolerated GDMT
Time Frame: Baseline to 90 days
|
The proportion of participants achieving optimal or maximally tolerated GDMT will be evaluated as a secondary outcome. For participants with HFrEF or HFmrEF, target GDMT consists of optimal or maximally tolerated doses of an evidence-based beta-blocker and an ARNi (or ACE inhibitor/ARB if ARNi is not tolerated), an MRA at target dose, and an SGLT2 inhibitor. For participants with HFpEF, target GDMT consists of an optimal or maximally tolerated dose of an ARNi or ARB (preferred over ACE inhibitor) and any dose of an SGLT2 inhibitor and an MRA (finerenone or spironolactone). GDMT prescription will be assessed via electronic medical record and pharmacy review. |
Baseline to 90 days
|
|
Heart Failure Collaboratory GDMT composite score
Time Frame: Baseline to 180 days
|
GDMT utilization across all medication classes will also be assessed using the well-validated and prognostically meaningful composite HF Collaboratory score. The Heart Failure Collaboratory (HFC) GDMT score is a validated composite that measures overall guideline-directed medical therapy use. Points are assigned for prescription of each drug class (beta-blocker, ACEi/ARB/ARNi, MRA, and SGLT2i) and weighted by percentage of target dose. Higher scores reflect more complete therapy optimization. |
Baseline to 180 days
|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score
Time Frame: Baseline to 180 days
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score. The KCCQ is a well-validated, HF-specific, patient-reported outcome measure and an FDA-endorsed measure of symptom and functional benefit. Scores range from 0 to 100, with higher scores indicating better health status. |
Baseline to 180 days
|
|
Change in mean daily step count
Time Frame: Baseline to 90 days, and baseline to 180 days
|
Change in mean daily step count, captured continuously via the wrist-worn activity device with remote monitoring. Step count provides an objective, continuously captured functional outcome that complements patient-reported quality of life and is less susceptible to reporting bias in this open-label design. |
Baseline to 90 days, and baseline to 180 days
|
|
Implementation outcomes assessed using the RE-AIM framework
Time Frame: Through study completion, up to 60 months
|
Implementation will be evaluated using the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework, with implementation assessed as fidelity. To understand contextual factors influencing implementation success, an explanatory sequential mixed-methods approach will combine quantitative implementation metrics with qualitative interviews of clinicians (n=12) and patients (n=36, stratified by study arm) to explore barriers, facilitators, acceptability, and differential effectiveness across patient subgroups, including age, sex, race/ethnicity, and socioeconomic position. Real-world implementation assessment is essential for translation beyond the trial setting. |
Through study completion, up to 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ambarish Pandey, MD, University of Michigan
Publications and helpful links
General Publications
- Harrington RA, Califf RM, Balamurugan A, Brown N, Benjamin RM, Braund WE, Hipp J, Konig M, Sanchez E, Joynt Maddox KE. Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020 Mar 10;141(10):e615-e644. doi: 10.1161/CIR.0000000000000753. Epub 2020 Feb 10.
- Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
- Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, Januzzi JL Jr, Yancy CW. 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-1878. doi: 10.1016/j.jacc.2023.03.393. Epub 2023 Apr 19. No abstract available.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
- Desai AS, Maclean T, Blood AJ, Bosque-Hamilton J, Dunning J, Fischer C, Fera L, Smith KV, Wagholikar K, Zelle D, Gaziano T, Plutzky J, Scirica B, MacRae CA. Remote Optimization of Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2020 Dec 1;5(12):1430-1434. doi: 10.1001/jamacardio.2020.3757.
- Brahmbhatt DH, Ross HJ, O'Sullivan M, Artanian V, Mueller B, Runeckles K, Steve Fan CP, Rac VE, Seto E; Medly Titrate Study Team. The Effect of Using a Remote Patient Management Platform in Optimizing Guideline-Directed Medical Therapy in Heart Failure Patients: A Randomized Controlled Trial. JACC Heart Fail. 2024 Apr;12(4):678-690. doi: 10.1016/j.jchf.2024.02.008.
- Loccoh EC, Joynt Maddox KE, Wang Y, Kazi DS, Yeh RW, Wadhera RK. Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States. J Am Coll Cardiol. 2022 Jan 25;79(3):267-279. doi: 10.1016/j.jacc.2021.10.045.
- Manemann SM, St Sauver J, Henning-Smith C, Finney Rutten LJ, Chamberlain AM, Fabbri M, Weston SA, Jiang R, Roger VL. Rurality, Death, and Healthcare Utilization in Heart Failure in the Community. J Am Heart Assoc. 2021 Feb 16;10(4):e018026. doi: 10.1161/JAHA.120.018026. Epub 2021 Feb 3.
- Eberly LA, Tennison A, Mays D, Hsu CY, Yang CT, Benally E, Beyuka H, Feliciano B, Norman CJ, Brueckner MY, Bowannie C, Schwartz DR, Lindsey E, Friedman S, Ketner E, Detsoi-Smiley P, Shyr Y, Shin S, Merino M. Telephone-Based Guideline-Directed Medical Therapy Optimization in Navajo Nation: The Hozho Randomized Clinical Trial. JAMA Intern Med. 2024 Jun 1;184(6):681-690. doi: 10.1001/jamainternmed.2024.1523.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HUM00297658
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Please contact the study team.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.